SLXNW NASDAQ
Jerusalem, TA 9112001
IL
Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths. Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer. Additionally, the company is advancing Prostate-LODER through preclinical studies for prostate cancer, and GBM-LODER, also in preclinical stages, to address Glioblastoma Multiforme, a severe primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Shirvan Mitchell | S-Sale | 22,818 | $1.36 | 2026-03-26 |
| Noy Shlomo | A-Award | 9,091 | — | 2026-02-20 |
| Noy Shlomo | A-Award | 10,685 | $1.65 | 2026-02-20 |
| Alon Ruth | A-Award | 9,091 | — | 2026-02-20 |
| Shirvan Mitchell | A-Award | 49,726 | — | 2026-02-20 |